Resilient Pharmaceuticals resubmits MDMA therapy NDA to FDA

Resilient Pharmaceuticals has resubmitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for MDMA-assisted therapy to treat Post-Traumatic Stress Disorder (PTSD). The resubmission is being made without a new Phase 3 clinical trial.

The move follows a Complete Response Letter issued by the FDA in August 2024, which requested further research regarding safety characterization, the durability of patient response, and methods to mitigate bias. The Multidisciplinary Association for Psychedelic Studies (MAPS), which funded the original clinical trials completed in 2022, noted that the new application aims to address these concerns using existing data.

This development coincides with the FDA’s July 2026 publication of final guidance on psychedelic drug clinical investigations. The guidance establishes standards for clinical trial design, therapist-delivered interventions, and long-term follow-up, addressing the specific regulatory areas identified in the previous rejection.